Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals Announces Agreement with the FDA on a Special Protocol Assessment for Planned Phase 3 Carfilzomib Combination Trial in Relapsed Multiple Myeloma
Published in Medical Letter on the CDC and FDA, February 21st, 2010
Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) announced that the company reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the Phase 3 international randomized trial. This pivotal trial, which is expected to begin in the first half of 2010, will enroll patients with relapsed multiple myeloma following treatment with one to three prior regimens. It is designed to evaluate the efficacy of carfilzomib in combination with lenalidomide and low dose dexamethasone, versus lenalidomide and low dose dexamethasone alone.
"The SPA enables us to initiate this carfilzomib Phase 3 combination trial in the first half of this year...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- American Journal of Pathology
Of swine, birds and men -- pandemic H1N1 flu - Angiology
Study results from D. Calcagno and colleagues broaden understanding of angiology - Health Discovery Corporation
Vermillion Pays Health Discovery Corporation Final Patent Infringement Settlement Payment - MedImmune
Pivotal Trial Results for Motavizumab Published in Current Issue of 'Pediatrics' - Pervasis Therapeutics, Inc.
Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel - Pharmaceuticals
Data on pharmaceuticals detailed by S.R. Taylor and co-authors - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
